Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Verastem Oncology Q4 2025 Earnings Call - Commercial launch gains traction with $30.9M revenue since approval, VS-7375 advanced toward registration-directed trials
Verastem closed 2025 as a newly commercial company after FDA approval of the avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Since approval in May, May...
- Verastem became a commercial-stage company in 2025 following FDA approval of avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, with approval delivered nearly two months ahead of the PDUFA date.
- Net product revenue for the launch period May through December 2025 was $30.9 million, including $17.5 million in Q4 2025, signaling early commercial traction.
- Nearly 300 prescribers had written scripts through February 2026, prescriptions split roughly 60/40 GynOnc to MedOnc, and more than half of prescriptions originate in academic centers.
- +12 more takeaways
MicroVision Q4 2025 Earnings Call - Acquisitions accelerate Lidar 2.0 shift, guiding $10M-$15M revenue and $65M-$70M cash burn in 2026
MicroVision used the Q4 and full-year 2025 call to reposition itself as a consolidated lidar vendor for automotive, industrial, and security and defense, leaning on recent Luminar and Scantinel acquis...
- Strategic pivot to 'Lidar 2.0': MicroVision says industry is moving from hardware-spec races to value-driven, software-enabled, design-to-cost solutions focused on scalable deployments across multiple end markets.
- Material acquisitions: Luminar and Scantinel were highlighted as transformational, adding Iris and Halo long-range products, a 1550 nm FMCW capability, and about 30 new Luminar customer relationships.
- Product portfolio breadth: MicroVision now claims a full-stack portfolio spanning MOVIA short-range sensors (MOVIA L and MOVIA S), Iris and Halo long-range sensors, 1550 nm FMCW from Scantinel, plus MOSAIK and Sentinel software for perception and point-cloud processing.
- +13 more takeaways
Alto Ingredients Q4 2025 Earnings Call - Strategic realignment lifts margins, CO2 and 45Z tailwinds
Alto delivered a clear rebound in 2025, turning a multi-year loss into positive earnings by tightening costs, optimizing assets, and leaning into CO2 and premium export markets. Q4 net income swung to...
- Q4 2025 net income attributable to common stockholders was $21.5 million, about $0.28 per diluted share, a roughly $63.5 million improvement versus Q4 2024.
- Adjusted EBITDA for Q4 was $27.9 million, and for full-year 2025 was $44.7 million, up approximately $35.6 million and $53.2 million year over year respectively.
- Primary drivers of improvement were stronger crush margins (+$0.15 per gallon year over year, contributing about $8 million), higher renewable fuel export sales (about $5 million), sale of Oregon carbon credits ($2.9 million), and staffing reductions (about $2.6 million).
- +12 more takeaways
Grocery Outlet Fourth Quarter 2025 Earnings Call - Leadership Owns Unacceptable Q4; Rebuilds Opportunistic Mix, Closes 36 Stores
Grocery Outlet did not hide the damage. Management called the fourth quarter unacceptable, took responsibility, and laid out a blunt turnaround: restore the opportunistic product flow that defines the...
- CEO Jason Potter said Q4 results were unacceptable and he owns fixing them, signaling accountability at the top.
- Comparable store sales declined 80 basis points in Q4 excluding an extra 53rd week; average transaction size fell 170 basis points while traffic rose 90 basis points.
- Q4 net sales were $1.22 billion, including $82.4 million from a 53rd week; excluding that week, revenue rose 3.2% year over year driven by new stores but offset by comps decline.
- +12 more takeaways
OmniAb Q4 2025 Earnings Call - Partner Pipeline Matures, OmniUltra and xPloration Drive New Growth
OmniAb closed 2025 with clear scale in its partner business and two fresh commercial plays. The company finished the year with 107 partners and 407 active programs, a meaningful uptick in new program ...
- Partner scale: OmniAb ended 2025 with 107 partners and 407 active programs, a net increase of 44 programs for the year.
- Program additions and attrition: 84 program additions in 2025, 40 terminations, and 25 program advancement events including 16 discovery->preclinical and 4 preclinical->phase 1 moves.
- Clinical traction: 32 active clinical and approved products at year-end, and 1 program reached the registration stage during 2025.
- +12 more takeaways
Pulmonx Q4 2025 Earnings Call - CEO Returns, Re-focuses Sales Force and Cuts Costs to Drive U.S. Rebound
Pulmonx ended 2025 with mixed results, management says the shortfall was largely self-inflicted and the fix is internal. Revenue in Q4 fell to $22.6 million, down 5% year over year, while full-year re...
- CEO Glen French returned and conducted a line-by-line review, concluding 2025 underperformance was largely due to internal execution and organizational choices rather than market collapse.
- Total worldwide revenue in Q4 2025 was $22.6 million, down 5% year over year; full-year revenue was $90.5 million, up 8% from 2024.
- U.S. revenue in Q4 was $14.1 million, an 11% decline versus prior year; U.S. full-year revenue was $57 million, up 1% year over year.
- +12 more takeaways
Red Violet Q4 2025 Earnings Call - Record quarter: 20% revenue growth, strong margins, and deepening enterprise traction
Red Violet closed 2025 with a clean, muscular quarter. Revenue hit a record $23.4 million, up 20% year over year, while adjusted gross profit and adjusted EBITDA expanded, producing unusually high mar...
- Record Q4 revenue of $23.4 million, up 20% year over year.
- Adjusted gross profit for the quarter reached $19.5 million, adjusted gross margin 83% for the quarter; company cited 84% for full year.
- Adjusted EBITDA was $5.9 million in Q4, up 33% year over year, producing a 25% adjusted EBITDA margin for the quarter; full-year adjusted EBITDA was $31.0 million, 34% margin.
- +17 more takeaways
Sight Sciences Fourth Quarter 2025 Earnings Call - Reimbursed TearCare Launch Provides Early Traction While OMNI Holds Steady
Sight Sciences closed 2025 on firmer footing. Q4 revenue was $20.4 million, up 7% year over year, driven by a steady interventional glaucoma business and the first real commercial glimpse of reimburse...
- Total Q4 2025 revenue was $20.4 million, a 7% increase year over year.
- Interventional glaucoma (IG) revenue was $19.7 million, up 5% year over year and flat sequentially, near the top end of guidance.
- Interventional dry eye (IDE) revenue was $0.7 million in Q4, up from $0.3 million a year earlier, reflecting early reimbursed activity.
- +16 more takeaways
ChargePoint Q4 FY2026 Earnings Call - Return to growth driven by product ramps, record subscription margins, and AI-driven efficiency
ChargePoint closed fiscal 2026 on a cautious high note. Q4 revenue came in at $109 million, at the top of guidance, marking sequential and year-over-year growth, while non-GAAP gross margin hit a reco...
- Q4 revenue $109 million, at the high end of guidance, up 7% year-over-year and 3% sequentially.
- Non-GAAP gross margin hit a record 33% in Q4, up 3 percentage points year-over-year.
- Subscription revenue was $42 million (39% of revenue); subscription margin reached a GAAP record of 64%, reflecting scale and service efficiencies.
- +15 more takeaways
Smith Micro Software Q4 2025 Earnings Call - Phone-first SafePath OS, CEO succession, and founder-funded bridge to profitability
Smith Micro closed 2025 with clear strategic pivots and a tightened cost base, even as top-line revenue slid. Q4 revenue was $4.0 million, down 20% year over year, and full-year revenue fell to $17.4 ...
- Q4 2025 revenue was $4.0 million, down 20% year over year, and down 7% sequentially versus Q3 2025.
- Full-year 2025 revenue was $17.4 million, a 16% decline from $20.6 million in 2024.
- Management is pursuing a phone-first SafePath OS strategy focused on kids and seniors, with the senior solution said to more than double the total addressable market.
- +17 more takeaways